Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer
Eastham, James A., Halabi, Susan , Monk, J. Paul, Beltran, Himisha , Evans, Christopher P. , Clinton, Steven K. , Watt, Colleen, Sanda, Martin G. , Hahn, Olwen, Taplin, Mary-Ellen, Parsons, J. Kellogg , Mohler, James L. , Hillman, David W. , Halabi, Susan , Heller, Glenn , Gleave, Martin , Szmulewitz, Russell Z , Coleman, Jonathan , George, Saby , Taplin, Mary‐Ellen , Small, Eric J. , Morris, Michael J.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2020 | Volume: 38 | Issue: 26 | Pages: 3042-3050

10.1200/jco.20.00315 | PMID 32706639 Get It

PURPOSE Radical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression–free survival (BPFS) over RP alone. PATIENTS AND METHODS Men with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m 2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS). RESULTS In total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, −0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone. CONCLUSION The primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.
Embolization of Brain Arteriovenous Malformations With Versus Without Onyx Before Stereotactic Radiosurgery
Chen, Ching‐Jen , Ding, Dale , Lee, Cheng‐Chia , Kearns, Kathryn N. , Pomeraniec, I. Jonathan , Cifarelli, Christopher P. , Arsanious, David, Liščák, Roman , Hanuška, Jaromír, Woo, Shiao Y. , Ironside, Natasha , Warnick, Ronald E. , Mathieu, David , Mureb, Monica , Benjamin, Carolina , Feliciano, Caleb , Rodríguez‐Mercado, Rafael, Cockroft, Kevin M. , Simon, Scott D. , Mackley, Heath B., Zammar, Samer G. , Patel, Neel, Padmanaban, Varun , Beatson, Nathan, Saylany, Anissa , Lee, John, Sheehan, Jason P. , May, Jaromír , Ding, Dale , Mathieu, David , Chen, Ching-Jen , Williams, Brian J. , Yusuf, Mehran Behruj , Trifiletti, Daniel M. , Kondziolka, Douglas , Lee, John

Mayo Clinic

Neurosurgery | July 23, 2020 | Volume: 88 | Issue: 2 | Pages: 366-374

10.1093/neuros/nyaa370 | PMID 32860409 Get It

Abstract BACKGROUND Embolization of brain arteriovenous malformations (AVMs) using ethylene-vinyl alcohol copolymer (Onyx) embolization may influence the treatment effects of stereotactic radiosurgery (SRS) differently than other embolysates. OBJECTIVE To compare the outcomes of pre-SRS AVM embolization with vs without Onyx through a multicenter, retrospective matched cohort study. METHODS We retrospectively reviewed International Radiosurgery Research Foundation AVM databases from 1987 to 2018. Embolized AVMs treated with SRS were selected and categorized based on embolysate usage into Onyx embolization (OE + SRS) or non-Onyx embolization (NOE + SRS) cohorts. The 2 cohorts were matched in a 1:1 ratio using de novo AVM features for comparative analysis of outcomes. RESULTS The matched cohorts each comprised 45 patients. Crude AVM obliteration rates were similar between the matched OE + SRS vs NOE + SRS cohorts (47% vs 51%; odds ratio [OR] = 0.837, P = .673). Cumulative probabilities of obliteration were also similar between the OE + SRS vs NOE + SRS cohorts (subhazard ratio = 0.992, P = .980). Rates of post-SRS hemorrhage, all-cause mortality, radiation-induced changes, cyst formation, and embolization-associated complications were similar between the matched cohorts. Sensitivity analysis for AVMs in the OE + SRS cohort embolized with Onyx alone revealed a higher rate of asymptomatic embolization-associated complications in this subgroup compared to the NOE + SRS cohort (36% vs 15%; OR = 3.297, P = .034), but the symptomatic complication rates were similar. CONCLUSION Nidal embolization using Onyx does not appear to differentially impact the outcomes of AVM SRS compared with non-Onyx embolysates. The embolic agent selected for pre-SRS AVM embolization should reflect both the experience of the neurointerventionalist and target of endovascular intervention.
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Rivera, Donna R. , Peters, Solange , Shah, Dimpy P. , Kuderer, Nicole M. , Hsu, Chih–Yuan , Rubinstein, Samuel M. , Lee, Brendan J., Choueiri, Toni K. , Lopes, Gilberto , Grivas, Petros , Arcobello, Jonathan , Bakouny, Ziad , Doroshow, Deborah B. , Egan, Pamela , Fecher, Leslie A. , Friese, Christopher R. , Galsky, Matthew D. , Gupta, Shilpa , Hálfdánarson, Þorvarður R. , Halmos, Balázs , Khaki, Ali Raza , Lemmon, Christopher A. , Mishra, Sanjay , Puc, Matthew , Revankar, Sanjay G. , Schapira, Lidia , Schmidt, Andrew , Shah, Sumit , Wu, Julie , Xie, Zhuoer , Yeh, Albert C. , Zhu, Huili , Shyr, Yu , Grivas, Petros , Bakouny, Ziad , Galsky, Matthew D , Goel, Sanjay , Halfdanarson, Thorvardur R , Hawley, Jessica E , Mishra, Sanjay , Pennell, Nathan A , Puc, Matthew M , Revankar, Sanjay G , Wu, Julie T , Yeh, Albert C , Warner, Jeremy L , Peters, Solange , Choueiri, Toni K , Xie, Zhuoer , Khaki, Ali Raza , Panagiotou, Orestis A. , Painter, Corrie , Rini, Brian I. , Thompson, Michael A. , Farmakiotis, Dimitrios , Goel, Sanjay , Hawley, Jessica E. , Olszewski, Adam J. , Schwartz, Gary K. , Lyman, Gary H , Warner, Jeremy L.

Mayo Clinic

Cancer Discovery | July 22, 2020 | Volume: 10 | Issue: 10 | Pages: 1514-1527

10.1158/2159-8290.cd-20-0941 | PMID 32699031 Get It

Abstract Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. Significance: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access. This article is highlighted in the In This Issue feature, p. 1426
Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock*
Roberts, Russel J. , Patel, Gourang , Chen, Jen‐Ting , Phillips, Kristy M. , Lopez, Natasha , Qadir, Nida , Cairns, Charles B. , Mathews, Kusum S. , Park, Pauline, Khan, Akram , Gilmore, James F. , Brown, Anne Rain , Tsuei, Betty J., Handzel, Michele, Chang, Alfredo Lee, Herbert, James T. , Martinez, Anthony , Tonna, Joseph E. , Nazer, Lama , Heavner, Mojdeh S. , Pender, Erin, Chambers, Lauren, Kenes, Michael T. , Kaufman, David A. , Downey, April, Brown, Brent R. , Chaykosky, Darlene, Wolff, Armand, Smith, Michael , Nault, Katie, Gong, Michelle N. , Sevransky, Jonathan, Lat, Ishaq , Network, on behalf of the Observation of VariatiOn in fLUids adMinistEred in shock-CHaracterizAtion of vaSoprEssor Requirements in Shock (VOLUME-CHASERS) Study Group and SCCM Discovery, Tonna, Joseph E. , Heavner, Mojdeh S , Khan, Akram , Miano, Todd A. , Hammond, Drayton A , Kashani, Kianoush , Park, Pauline K. , Duggal, Abhijit , Lanspa, Michael J. , Ammar, Mahmoud A , Network, on behalf of the Observation of VariatiOn in fLUids adMinistEred in shock-CHaracterizAtion of vaSoprEssor Requirements in Shock (VOLUME-CHASERS) Study Group and SCCM Discovery

Mayo Clinic

Critical Care Medicine | July 22, 2020 | Volume: 48 | Issue: 10 | Pages: 1445-1453

10.1097/ccm.0000000000004476 | PMID 32706559 Get It

Objectives: The objectives of this study were to: 1) determine the association between vasopressor dosing intensity during the first 6 hours and first 24 hours after the onset of septic shock and 30-day in-hospital mortality; 2) determine whether the effect of vasopressor dosing intensity varies by fluid resuscitation volume; and 3) determine whether the effect of vasopressor dosing intensity varies by dosing titration pattern. Design: Multicenter prospective cohort study between September 2017 and February 2018. Vasopressor dosing intensity was defined as the total vasopressor dose infused across all vasopressors in norepinephrine equivalents. Setting: Thirty-three hospital sites in the United States ( n = 32) and Jordan ( n = 1). Patients: Consecutive adults requiring admission to the ICU with septic shock treated with greater than or equal to 1 vasopressor within 24 hours of shock onset. Interventions: None. Measurements and Main Results: Out of 1,639 patients screened, 616 were included. Norepinephrine (93%) was the most common vasopressor. Patients received a median of 3,400 mL (interquartile range, 1,851–5,338 mL) during the 24 hours after shock diagnosis. The median vasopressor dosing intensity during the first 24 hours of shock onset was 8.5 μg/min norepinephrine equivalents (3.4–18.1 μg/min norepinephrine equivalents). In the first 6 hours, increasing vasopressor dosing intensity was associated with increased odds ratio of 30-day in-hospital mortality, with the strength of association dependent on concomitant fluid administration. Over the entire 24 hour period, every 10 μg/min increase in vasopressor dosing intensity was associated with an increased risk of 30-day mortality (adjusted odds ratio, 1.33; 95% CI, 1.16–1.53), and this association did not vary with the amount of fluid administration. Compared to an early high/late low vasopressor dosing strategy, an early low/late high or sustained high vasopressor dosing strategy was associated with higher mortality. Conclusions: Increasing vasopressor dosing intensity during the first 24 hours after septic shock was associated with increased mortality. This association varied with the amount of early fluid administration and the timing of vasopressor titration.
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy
Nair, Dileep , Laxer, Kenneth D. , Weber, Peter, Murro, Anthony M., Park, Yong D., Barkley, Gregory L., Smith, Brien, Gwinn, Ryder P. , Doherty, Michael J. , Zimmerman, Richard S. , Bergey, Gregory K. , Anderson, William S. , Heck, Christianne, Liu, Charles Y. , Lee, Ricky W. , Sadler, Toni, Duckrow, Robert B., Wharen, Robert E. , Tatum, William O. , Srinivasan, Shraddha, Agostini, Mark, Alexopoulos, Andreas V. , Jobst, Barbara C. , Roberts, David W. , Salanova, Vicenta , Witt, Thomas C., Cash, Sydney S. , Halford, Jonathan J. , Spencer, David , Ernst, Lia , Skidmore, Christopher , Sperling, Michael R. , Miller, Ian , Geller, Eric B., Berg, Michel J., Fessler, A. James, Rutecki, Paul , Mizrahi, Eli M., Shields, Donald C. , Schwartz, Theodore H. , Labar, Douglas, Fountain, Nathan B. , Elias, W. Jeff, Olejniczak, Piotr W., Villemarette-Pittman, Nicole R. , Eisenschenk, Stephan, Roper, Steven N. , Boggs, Jane , Courtney, Tracy A., Sun, Felice T., Seale, Cairn G. , Miller, Kathy L. , Skarpaas, Tara L. , Morrell, Martha J. , Study, on behalf of the RNS System LTT, Meador, Kimford J. , Vossler, David G. , Hays, Ryan , Liow, Kore , Nair, Dileep R, Weber, Peter B, Smith, Brien J, Noe, Katherine H. , McKhann, Guy M. , Agostini, Mark A, Alexopoulos, Andreas V , Edwards, Jonathan C, Spencer, David C, Skidmore, Christopher T., Goldman, Alica M. , Gross, Robert E, Labar, Douglas R, Boggs, Jane G, Sperling, Michael R , Halford, Jonathan J , Fountain, Nathan , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J , Ernst, Lia D , Hirsch, Lawrence J. , Cole, Andrew J. , Worrell, Gregory A. , Lundstrom, Brian N. , Edwards, Jonathan C. W. , Gross, Robert E. , Study, on behalf of the RNS System LTT

Mayo Clinic

Neurology | July 20, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010154 | PMID 32690786 Get It

Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis, and treatmen
Ng, Bobby G. , Eklund, Erik A. , Shiryaev, Sergey A., Dong, Yin Yao , Abbott, Mary‐Alice , Asteggiano, Carla , Bamshad, Michael J. , Barr, Eileen , Bernstein, Jonathan A. , Chelakkadan, Shabeed, Ciliberto, Michael A. , Cousin, Janice, Gardiner, Fiona, Ghosh, Suman , Graf, W. , Grünewald, Stephanie , Hammond, Katherine, Hauser, Natalie , Hoganson, George, Houck, Kimberly , Kohler, Jennefer N., Liu, Pengfei , Madathil, Sujana , McCormack, Colleen E., Meeks, Naomi, Miller, Rebecca L. , Monaghan, Kristin G. , Nickerson, Deborah A. , Palculict, Timothy Blake, Papazoglu, Gabriela M., Pletcher, Beth A. , Scheffer, Ingrid E. , Schenone, Andrea, Schnur, Rhonda E. , Si, Yue , Rowe, Leah J., Russi, Alvaro H. Serrano, Russo, Rossana Sanchez , Thabet, Farouq , Tuite, Allysa , Villanueva, Marıá Mercedes, Webster, Richard , Wilson, Dorcas, Zalan, Alice, Wolfe, Lynne A. , Rhodes, Lindsay, Scheffer, Ingrid E , Ng, Bobby G , Christodoulou, John , Chung, Wendy K. , Morava, Éva , Larson, Austin , Miller, Rebecca, Monaghan, Kristin G. , Rowe, Leah J., Wang, Raymond , Rosenfeld, Jill A. , Freeze, Hudson H.

Mayo Clinic

Journal of Inherited Metabolic Disease | July 18, 2020 | Volume: 43 | Issue: 6 | Pages: 1333-1348

10.1002/jimd.12290 | PMID 32681751 Get It

Abstract Asparagine‐linked glycosylation 13 homolog ( ALG13 ) encodes a nonredundant, highly conserved, X‐linked uridine diphosphate (UDP)‐ N ‐acetylglucosaminyltransferase required for the synthesis of lipid linked oligosaccharide precursor and proper N‐linked glycosylation. De novo variants in ALG13 underlie a form of early infantile epileptic encephalopathy known as EIEE36, but given its essential role in glycosylation, it is also considered a congenital disorder of glycosylation (CDG), ALG13‐CDG. Twenty‐four previously reported ALG13‐CDG cases had de novo variants, but surprisingly, unlike most forms of CDG, ALG13‐CDG did not show the anticipated glycosylation defects, typically detected by altered transferrin glycosylation. Structural homology modeling of two recurrent de novo variants, p.A81T and p.N107S, suggests both are likely to impact the function of ALG13. Using a corresponding ALG13‐deficient yeast strain, we show that expressing yeast ALG13 with either of the highly conserved hotspot variants rescues the observed growth defect, but not its glycosylation abnormality. We present molecular and clinical data on 29 previously unreported individuals with de novo variants in ALG13 . This more than doubles the number of known cases. A key finding is that a vast majority of the individuals presents with West syndrome, a feature shared with other CDG types. Among these, the initial epileptic spasms best responded to adrenocorticotropic hormone or prednisolone, while clobazam and felbamate showed promise for continued epilepsy treatment. A ketogenic diet seems to play an important role in the treatment of these individuals.
Safety and efficacy of (+)‐epicatechin in subjects with Friedreich's ataxia: A phase II , open‐label, prospective study
Qureshi, M. Yasir , Clark, Vicki M., Johnson, Jonathan N. , Moutvic, Margaret A., Driscoll, Sherilyn W. , Kemppainen, Jennifer L., Badley, Andrew D. , Tebben, Peter J. , Wackel, Philip L. , Oglesbee, Devin , Glockner, James F., Schreiner, George F., Touchette, Jillienne C. , Gavrilova, Ralitza H. , Qureshi, Muhammad Yasir, Patterson, Marc C. , Clark, Vicki, Anderson, Jeff R , Glockner, James, Qureshi, Muhammad Y , Oglesbee, Devin , Badley, Andrew D , Tebben, Peter , Huston, John , Anderson, Jeff R., Dugar, Sundeep

Mayo Clinic

Journal of Inherited Metabolic Disease | July 17, 2020 | Volume: 44 | Issue: 2 | Pages: 502-514

10.1002/jimd.12285 | PMID 32677106 Get It

Abstract Background (+)‐Epicatechin (EPI) induces mitochondrial biogenesis and antioxidant metabolism in muscle fibers and neurons. We aimed to evaluate safety and efficacy of (+)‐EPI in pediatric subjects with Friedreich's ataxia (FRDA). Methods This was a phase II, open‐label, baseline‐controlled single‐center trial including 10 participants ages 10 to 22 with confirmed FA diagnosis. (+)‐EPI was administered orally at 75 mg/d for 24 weeks, with escalation to 150 mg/d at 12 weeks for subjects not showing improvement of neuromuscular, neurological or cardiac endpoints. Neurological endpoints were change from baseline in Friedreich's Ataxia Rating Scale (FARS) and 8‐m timed walk. Cardiac endpoints were changes from baseline in left ventricular (LV) structure and function by cardiac magnetic resonance imaging (MRI) and echocardiogram, changes in cardiac electrophysiology, and changes in biomarkers for heart failure and hypertrophy. Results Mean FARS/modified (m)FARS scores showed nonstatistically significant improvement by both group and individual analysis. FARS/mFARS scores improved in 5/9 subjects (56%), 8‐m walk in 3/9 (33%), 9‐peg hole test in 6/10 (60%). LV mass index by cardiac MRI was significantly reduced at 12 weeks ( P = .045), and was improved in 7/10 (70%) subjects at 24 weeks. Mean LV ejection fraction was increased at 24 weeks ( P = .008) compared to baseline. Mean maximal septal thickness by echocardiography was increased at 24 weeks ( P = .031). There were no serious adverse events. Conclusion (+)‐EPI was well tolerated over 24 weeks at up to 150 mg/d. Improvement was observed in cardiac structure and function in subset of subjects with FRDA without statistically significant improvement in primary neurological outcomes. Synopsis A (+)‐epicatechin showed improvement of cardiac function, nonsignificant reduction of FARS/mFARS scores, and sustained significant upregulation of muscle‐regeneration biomarker follistatin.
Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia
Boes, Samuel, Botha, Hugo , Lowe, Val J. , Graff‐Radford, Jonathan , Whitwell, Jennifer L. , Josephs, Keith A. , Botha, Hugo , Boes, Samuel A. , Machulda, Mary M. , Utianski, Rene L. , Duffy, Joseph R.

Mayo Clinic

Neurocase | July 16, 2020 | Volume: 26 | Issue: 5 | Pages: 259-263

10.1080/13554794.2020.1795204 | PMID 32672090 Get It

Postoperative Critical Events Associated With Obstructive Sleep Apnea: Results From the Society of Anesthesia and Sleep Medicine Obstructive Sleep Apnea Registry
Bolden, Norman, Posner, Karen L. , Domino, Karen B. , Auckley, Dennis , Benumof, Jonathan L., Herway, Seth T., Hillman, David R. , Mincer, Shawn L., Overdyk, Frank J. , Warner, Lindsay L. , Samuels, David J., Weingarten, Toby N. , Chung, Frances

Mayo Clinic

Anesthesia & Analgesia | July 16, 2020 | Volume: 131 | Issue: 4 | Pages: 1032-1041

10.1213/ane.0000000000005005 | PMID 32925320 Get It

BACKGROUND: Obstructive sleep apnea (OSA) patients are at increased risk for pulmonary and cardiovascular complications; perioperative mortality risk is unclear. This report analyzes cases submitted to the OSA Death and Near Miss Registry, focusing on factors associated with poor outcomes after an OSA-related event. We hypothesized that more severe outcomes would be associated with OSA severity, less intense monitoring, and higher cumulative opioid doses. METHODS: Inclusion criteria were age ≥18 years, OSA diagnosed or suspected, event related to OSA, and event occurrence 1992 or later and <30 days postoperatively. Factors associated with death or brain damage versus other critical events were analyzed by tests of association and odds ratios (OR; 95% confidence intervals [CIs]). RESULTS: Sixty-six cases met inclusion criteria with known OSA diagnosed in 55 (83%). Patients were middle aged (mean = 53, standard deviation [SD] = 15 years), American Society of Anesthesiologists (ASA) III (59%, n = 38), and obese (mean body mass index [BMI] = 38, SD = 9 kg/m 2 ); most had inpatient (80%, n = 51) and elective (90%, n = 56) procedures with general anesthesia (88%, n = 58). Most events occurred on the ward (56%, n = 37), and 14 (21%) occurred at home. Most events (76%, n = 50) occurred within 24 hours of anesthesia end. Ninety-seven percent (n = 64) received opioids within the 24 hours before the event, and two-thirds (41 of 62) also received sedatives. Positive airway pressure devices and/or supplemental oxygen were in use at the time of critical events in 7.5% and 52% of cases, respectively. Sixty-five percent (n = 43) of patients died or had brain damage; 35% (n = 23) experienced other critical events. Continuous central respiratory monitoring was in use for 3 of 43 (7%) of cases where death or brain damage resulted. Death or brain damage was (1) less common when the event was witnessed than unwitnessed (OR = 0.036; 95% CI, 0.007–0.181; P < .001); (2) less common with supplemental oxygen in place (OR = 0.227; 95% CI, 0.070–0.740; P = .011); (3) less common with respiratory monitoring versus no monitoring (OR = 0.109; 95% CI, 0.031–0.384; P < .001); and (4) more common in patients who received both opioids and sedatives than opioids alone (OR = 4.133; 95% CI, 1.348–12.672; P = .011). No evidence for an association was observed between outcomes and OSA severity or cumulative opioid dose. CONCLUSIONS: Death and brain damage were more likely to occur with unwitnessed events, no supplemental oxygen, lack of respiratory monitoring, and coadministration of opioids and sedatives. It is important that efforts be directed at providing more effective monitoring for OSA patients following surgery, and clinicians consider the potentially dangerous effects of opioids and sedatives—especially when combined—when managing OSA patients postoperatively.
Predicting future rates of tau accumulation on PET
Jack, Clifford R. , Wiste, Heather J. , Weigand, Stephen D. , Therneau, Terry M. , Lowe, Val J. , Botha, Hugo , Graff‐Radford, Jonathan , Ferman, Tanis J. , Kantarci, Kejal , Vemuri, Prashanthi , Whitwell, Jennifer L. , Josephs, Keith A. , Senjem, Matthew L. , Gunter, Jeffrey L. , Petersen, Ronald C. , Josephs, Keith, Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Botha, Hugo , Ferman, Tanis J , Knopman, David S. , Jones, David T. , Boeve, Bradley F. , Mielke, Michelle M. , Schwarz, Christopher G.

Mayo Clinic

Brain | July 14, 2020 | Volume: 143 | Issue: 10 | Pages: 3136-3150

10.1093/brain/awaa248 | PMID 33094327 Get It

Abstract Clinical trials with anti-tau drugs will need to target individuals at risk of accumulating tau. Our objective was to identify variables available in a research setting that predict future rates of tau PET accumulation separately among individuals who were either cognitively unimpaired or cognitively impaired. All 337 participants had: a baseline study visit with MRI, amyloid PET, and tau PET exams, at least one follow-up tau PET exam; and met clinical criteria for membership in one of two clinical diagnostic groups: cognitively unimpaired (n = 203); or cognitively impaired (n = 134, a combined group of participants with either mild cognitive impairment or dementia with Alzheimer’s clinical syndrome). Our primary analyses were in these two clinical groups; however, we also evaluated subgroups dividing the unimpaired group by normal/abnormal amyloid PET and the impaired group by clinical phenotype (mild cognitive impairment, amnestic dementia, and non-amnestic dementia). Linear mixed effects models were used to estimate associations between age, sex, education, APOE genotype, amyloid and tau PET standardized uptake value ratio (SUVR), cognitive performance, cortical thickness, and white matter hyperintensity volume at baseline, and the rate of subsequent tau PET accumulation. Log-transformed tau PET SUVR was used as the response and rates were summarized as annual per cent change. A temporal lobe tau PET meta-region of interest was used. In the cognitively unimpaired group, only higher baseline amyloid PET was a significant independent predictor of higher tau accumulation rates (P &lt; 0.001). Higher rates of tau accumulation were associated with faster rates of cognitive decline in the cognitively unimpaired subgroup with abnormal amyloid PET (P = 0.03), but among the subgroup with normal amyloid PET. In the cognitively impaired group, younger age (P = 0.02), higher baseline amyloid PET (P = 0.05), APOE ε4 (P = 0.05), and better cognitive performance (P = 0.05) were significant independent predictors of higher tau accumulation rates. Among impaired individuals, faster cognitive decline was associated with faster rates of tau accumulation (P = 0.01). While we examined many possible predictor variables, our results indicate that screening of unimpaired individuals for potential inclusion in anti-tau trials may be straightforward because the only independent predictor of high tau rates was amyloidosis. In cognitively impaired individuals, imaging and clinical variables consistent with early onset Alzheimer’s disease phenotype were associated with higher rates of tau PET accumulation suggesting this may be a highly advantageous group in which to conduct proof-of-concept clinical trials that target tau-related mechanisms. The nature of the dementia phenotype (amnestic versus non-amnestic) did not affect this conclusion.